Skip to main content
Top
Published in: Heart and Vessels 9/2022

Open Access 09-04-2022 | Exercise Therapy | Original Article

Intensive exercise therapy for restenosis after superficial femoral artery stenting: the REASON randomized clinical trial

Authors: Tamon Kato, Takashi Miura, Shuhei Yamamoto, Yusuke Miyashita, Naoto Hashizume, Kyoko Shoin, Shinya Sasaki, Yusuke Kanzaki, Hisanori Yui, Shusaku Maruyama, Ayumu Nagae, Takahiro Sakai, Tatsuya Saigusa, Soichiro Ebisawa, Ayako Okada, Hirohiko Motoki, Uichi Ikeda, Koichiro Kuwahara, The REASON Investigators

Published in: Heart and Vessels | Issue 9/2022

Login to get access

Abstract

Endovascular treatment (EVT) is the main treatment for peripheral artery disease (PAD). Despite advances in device development, the restenosis rate remains high in patients with femoropopliteal lesions (FP). This study aimed to evaluate the effectiveness of exercise training in reducing the 1-year in-stent restenosis rate of bare metal nitinol stents for FPs. This prospective, randomized, open-label, multicenter study was conducted from January 2017 to March 2019. We randomized 44 patients who had claudication with de novo stenosis or occlusion of the FP into an intensive exercise group (n = 22) and non-intensive exercise group (n = 22). Non-intensive exercise was defined as walking for less than 30 min per session, fewer than three times a week. We assessed exercise tolerance using an activity meter at 1, 3, 6, and 12 months, and physiotherapists ensured maintenance of exercise quality every month. The primary endpoint was instant restenosis defined as a peak systolic velocity ratio > 2.5 on duplex ultrasound imaging. Kaplan–Meier analysis was used to evaluate the data. There were no significant differences in background characteristics between the groups. Six patients dropped out of the study within 1 year. In terms of the primary endpoint, intensive exercise significantly improved the patency rate of bare nitinol stents at 12 months. The 1-year freedom from in-stent restenosis rates were 81.3% in the intensive exercise group and 47.6% in the non-intensive exercise group (p = 0.043). No cases of stent fracture were observed in the intensive exercise group. Intensive exercise is safe and reduces in-stent restenosis in FP lesions after endovascular therapy for PAD. Clinical trial registration: University Hospital Medical Information Network Clinical Trials Registry (No. UMIN 000025259).
Literature
1.
go back to reference Selvin E, Erlinger TP (2004) Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999–2000. Circulation 110(6):738–743CrossRef Selvin E, Erlinger TP (2004) Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999–2000. Circulation 110(6):738–743CrossRef
2.
go back to reference Zeller T (2007) Current state of endovascular treatment of femoro-popliteal artery disease. Vasc Med 12(3):223–234CrossRef Zeller T (2007) Current state of endovascular treatment of femoro-popliteal artery disease. Vasc Med 12(3):223–234CrossRef
3.
go back to reference Balzer JO, Thalhammer A, Khan V, Zangos S, Vogl TJ, Lehnert T (2010) Angioplasty of the pelvic and femoral arteries in PAOD: results and review of the literature. Eur J Radiol 75(1):48–56CrossRef Balzer JO, Thalhammer A, Khan V, Zangos S, Vogl TJ, Lehnert T (2010) Angioplasty of the pelvic and femoral arteries in PAOD: results and review of the literature. Eur J Radiol 75(1):48–56CrossRef
4.
go back to reference Morris-Stiff G, Ogunbiyi S, Rees J, Davies CJ, Hicks E, Lewis MH (2011) Variations in the anatomical distribution of peripheral vascular disease according to gender. Ann R Coll Surg Engl 93(4):306–309CrossRef Morris-Stiff G, Ogunbiyi S, Rees J, Davies CJ, Hicks E, Lewis MH (2011) Variations in the anatomical distribution of peripheral vascular disease according to gender. Ann R Coll Surg Engl 93(4):306–309CrossRef
5.
go back to reference Krankenberg H, Schluter M, Steinkamp HJ, Burgelin K, Scheinert D, Schulte KL, Minar E, Peeters P, Bosiers M, Tepe G, Reimers B, Mahler F, Tubler T, Zeller T (2007) Nitinol stent implantation versus percutaneous transluminal angioplasty in superficial femoral artery lesions up to 10 cm in length: the Femoral Artery Stenting Trial (FAST). Circulation 116(3):285–292CrossRef Krankenberg H, Schluter M, Steinkamp HJ, Burgelin K, Scheinert D, Schulte KL, Minar E, Peeters P, Bosiers M, Tepe G, Reimers B, Mahler F, Tubler T, Zeller T (2007) Nitinol stent implantation versus percutaneous transluminal angioplasty in superficial femoral artery lesions up to 10 cm in length: the Femoral Artery Stenting Trial (FAST). Circulation 116(3):285–292CrossRef
6.
go back to reference Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG, TASC II Working Group (2007) Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg 45(Suppl S):S5–S67CrossRef Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG, TASC II Working Group (2007) Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg 45(Suppl S):S5–S67CrossRef
7.
go back to reference Soga Y, Iida O, Hirano K, Yokoi H, Nanto S, Nobuyoshi M (2010) Mid-term clinical outcome and predictors of vessel patency after femoropopliteal stenting with self-expandable nitinol stent. J Vasc Surg 52(3):608–615CrossRef Soga Y, Iida O, Hirano K, Yokoi H, Nanto S, Nobuyoshi M (2010) Mid-term clinical outcome and predictors of vessel patency after femoropopliteal stenting with self-expandable nitinol stent. J Vasc Surg 52(3):608–615CrossRef
8.
go back to reference Ohki T, Angle JF, Yokoi H, Jaff MR, Popma J, Piegari G, Kanaoka Y, OSPREY investigators, (2016) One-year outcomes of the US and Japanese regulatory trial of the Misago stent for treatment of superficial femoral artery disease (OSPREY Study). J Vasc Surg 63(3):370–376CrossRef Ohki T, Angle JF, Yokoi H, Jaff MR, Popma J, Piegari G, Kanaoka Y, OSPREY investigators, (2016) One-year outcomes of the US and Japanese regulatory trial of the Misago stent for treatment of superficial femoral artery disease (OSPREY Study). J Vasc Surg 63(3):370–376CrossRef
9.
go back to reference Iida O, Yokoi H, Soga Y, Inoue N, Suzuki K, Yokoi Y, Kawasaki D, Zen K, Urasawa K, Shintani Y, Miyamoto A, Hirano K, Miyashita Y, Tsuchiya T, Shinozaki N, Nakamura M, Isshiki T, Hamasaki T, Nanto S, STOP-IC investigators (2013) Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the sufficient treatment of peripheral intervention by cilostazol study. Circulation 127(23):2307–2315CrossRef Iida O, Yokoi H, Soga Y, Inoue N, Suzuki K, Yokoi Y, Kawasaki D, Zen K, Urasawa K, Shintani Y, Miyamoto A, Hirano K, Miyashita Y, Tsuchiya T, Shinozaki N, Nakamura M, Isshiki T, Hamasaki T, Nanto S, STOP-IC investigators (2013) Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the sufficient treatment of peripheral intervention by cilostazol study. Circulation 127(23):2307–2315CrossRef
10.
go back to reference Miura T, Miyashita Y, Sog Y, Hozawa K, Doijiri T, Ikeda U, Kuwahara K, DEBATE in SFA Investigators (2018) Drug-eluting versus bare-metal stent implantation with or without cilostazol in the treatment of the superficial femoral artery. Circ Cadiovasc Interv 11(8):e0006564 Miura T, Miyashita Y, Sog Y, Hozawa K, Doijiri T, Ikeda U, Kuwahara K, DEBATE in SFA Investigators (2018) Drug-eluting versus bare-metal stent implantation with or without cilostazol in the treatment of the superficial femoral artery. Circ Cadiovasc Interv 11(8):e0006564
11.
go back to reference Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, Fleisher LA, Fowkes FGR, Hamburg NM, Kinlay S, Lookstein R, Misra S, Mureebe L, Olin JW, Patel RAG, Regensteiner JG, Schanzer A, Shishehbor MH, Stewart KJ, Treat-Jacobson D, Walsh ME, Halperin JL, Levine GN, Al-Khatib SM, Birtcher KK, Bozkurt B, Brindis RG, Cigarroa JE, Curtis LH, Fleisher LA, Gentile F, Gidding S, Hlatky MA, Ikonomidis J, Joglar J, Pressler SJ, Wijeysundera DN (2017) 2016 AHA/ACC guideline on the management of patients with lower extremity periperal artery disease: executive summary. Vasc Med 22(3):NP1–NP43CrossRef Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, Fleisher LA, Fowkes FGR, Hamburg NM, Kinlay S, Lookstein R, Misra S, Mureebe L, Olin JW, Patel RAG, Regensteiner JG, Schanzer A, Shishehbor MH, Stewart KJ, Treat-Jacobson D, Walsh ME, Halperin JL, Levine GN, Al-Khatib SM, Birtcher KK, Bozkurt B, Brindis RG, Cigarroa JE, Curtis LH, Fleisher LA, Gentile F, Gidding S, Hlatky MA, Ikonomidis J, Joglar J, Pressler SJ, Wijeysundera DN (2017) 2016 AHA/ACC guideline on the management of patients with lower extremity periperal artery disease: executive summary. Vasc Med 22(3):NP1–NP43CrossRef
12.
go back to reference McDermott MM, Liu K, Guralnik JM, Criqui MH, Spring B, Tian L, Domanchuk K, Ferrucci L, Lloyd-Jones D, Kibbe M, Tao H, Zhao L, Liao Y, Rejeski WJ (2013) Home-based walking exercise intervention in peripheral artery disease: a randomized clinical trial. JAMA 310(1):57–65CrossRef McDermott MM, Liu K, Guralnik JM, Criqui MH, Spring B, Tian L, Domanchuk K, Ferrucci L, Lloyd-Jones D, Kibbe M, Tao H, Zhao L, Liao Y, Rejeski WJ (2013) Home-based walking exercise intervention in peripheral artery disease: a randomized clinical trial. JAMA 310(1):57–65CrossRef
13.
go back to reference Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, Fleisher LA, Fowkes FG, Hamburg NM, Kinlay S, Lookstein R, Misra S, Mureebe L, Olin JW, Patel RA, Regensteiner JG, Schanzer A, Shishehbor MH, Stewart KJ, Treat-Jacobson D, Walsh ME (2017) 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease. Circulation 135(12):e726–e779PubMed Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, Fleisher LA, Fowkes FG, Hamburg NM, Kinlay S, Lookstein R, Misra S, Mureebe L, Olin JW, Patel RA, Regensteiner JG, Schanzer A, Shishehbor MH, Stewart KJ, Treat-Jacobson D, Walsh ME (2017) 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease. Circulation 135(12):e726–e779PubMed
14.
go back to reference Parmenter BJ, Dieberg G, Smart NA (2015) Exercise training for management of peripheral arterial disease: a systematic review and meta-analysis. Sports Med 45(2):231–244CrossRef Parmenter BJ, Dieberg G, Smart NA (2015) Exercise training for management of peripheral arterial disease: a systematic review and meta-analysis. Sports Med 45(2):231–244CrossRef
15.
go back to reference Parmenter BJ, Dieberg G, Phipps G, Smart NA (2015) Exercise training for health-related quality of life in peripheral artery disease: a systematic review and meta-analysis. Vasc Med 20(1):30–40CrossRef Parmenter BJ, Dieberg G, Phipps G, Smart NA (2015) Exercise training for health-related quality of life in peripheral artery disease: a systematic review and meta-analysis. Vasc Med 20(1):30–40CrossRef
16.
go back to reference Murphy TP, Cutlip DE, Regensteiner JG, Mohler ER, Cohen DJ, Reynolds MR, Massaro JM, Lewis BA, Cerezo J, Oldenburg NC, Thum CC, Goldberg S, Jaff MR, Steffes MW, Comerota AJ, Ehrman J, Treat-Jacobson D, Walsh ME, Collins T, Badenhop DT, Bronas U, Hirsch AT, CLEVER Study Investigators (2012) Supervised exercise versus primary stenting for claudication resulting from aortoiliac peripheral artery disease: six-month outcomes from the claudication: exercise versus endoluminal revascularization (CLEVER) study. Circulation 125(1):130–139CrossRef Murphy TP, Cutlip DE, Regensteiner JG, Mohler ER, Cohen DJ, Reynolds MR, Massaro JM, Lewis BA, Cerezo J, Oldenburg NC, Thum CC, Goldberg S, Jaff MR, Steffes MW, Comerota AJ, Ehrman J, Treat-Jacobson D, Walsh ME, Collins T, Badenhop DT, Bronas U, Hirsch AT, CLEVER Study Investigators (2012) Supervised exercise versus primary stenting for claudication resulting from aortoiliac peripheral artery disease: six-month outcomes from the claudication: exercise versus endoluminal revascularization (CLEVER) study. Circulation 125(1):130–139CrossRef
17.
go back to reference Murphy TP, Cutlip DE, Regensteiner JG, Mohler ER, Cohen DJ, Reynolds MR, Massaro JM, Lewis BA, Cerezo J, Oldenburg NC, Thum CC, Jaff MR, Comerota AJ, Steffes MW, Abrahamsen IH, Goldberg S, Hirsch AT (2015) Supervised exercise, stent revascularization, or medical therapy for claudication due to aortoiliac peripheral artery disease: the CLEVER study. J Am Coll Cardiol 65:999–1009CrossRef Murphy TP, Cutlip DE, Regensteiner JG, Mohler ER, Cohen DJ, Reynolds MR, Massaro JM, Lewis BA, Cerezo J, Oldenburg NC, Thum CC, Jaff MR, Comerota AJ, Steffes MW, Abrahamsen IH, Goldberg S, Hirsch AT (2015) Supervised exercise, stent revascularization, or medical therapy for claudication due to aortoiliac peripheral artery disease: the CLEVER study. J Am Coll Cardiol 65:999–1009CrossRef
18.
go back to reference Soga Y, Iida O, Hirano K, Suzuki K, Tosaka A, Yokoi H, Nobuyoshi M (2011) Unity of new classification based on clinical and lesional factors after self-expandable nitinol stenting in the superficial femoral artery. J Vasc Surg 54(4):1058–1066CrossRef Soga Y, Iida O, Hirano K, Suzuki K, Tosaka A, Yokoi H, Nobuyoshi M (2011) Unity of new classification based on clinical and lesional factors after self-expandable nitinol stenting in the superficial femoral artery. J Vasc Surg 54(4):1058–1066CrossRef
19.
go back to reference Scheinert D, Scheinert S, Sax J, Piorkowski C, Braunlich S, Ulrich M, Biamino G, Schmidt A (2005) Prevalence and clinical impact of stent fractures after femoropopliteal stenting. J Am Coll Cardiol 45(2):312–315CrossRef Scheinert D, Scheinert S, Sax J, Piorkowski C, Braunlich S, Ulrich M, Biamino G, Schmidt A (2005) Prevalence and clinical impact of stent fractures after femoropopliteal stenting. J Am Coll Cardiol 45(2):312–315CrossRef
20.
go back to reference Stewart KJ, Hiatt WR, Regensteiner JG, Hirsch AT (2002) Exercise training for claudication. N Engl J Med 347(24):1941–1951CrossRef Stewart KJ, Hiatt WR, Regensteiner JG, Hirsch AT (2002) Exercise training for claudication. N Engl J Med 347(24):1941–1951CrossRef
21.
go back to reference Durand MJ, Gutterman DD (2014) Exercise and vascular function: How much is too much? Can J Physiol Pharmacol 92(7):551–557CrossRef Durand MJ, Gutterman DD (2014) Exercise and vascular function: How much is too much? Can J Physiol Pharmacol 92(7):551–557CrossRef
Metadata
Title
Intensive exercise therapy for restenosis after superficial femoral artery stenting: the REASON randomized clinical trial
Authors
Tamon Kato
Takashi Miura
Shuhei Yamamoto
Yusuke Miyashita
Naoto Hashizume
Kyoko Shoin
Shinya Sasaki
Yusuke Kanzaki
Hisanori Yui
Shusaku Maruyama
Ayumu Nagae
Takahiro Sakai
Tatsuya Saigusa
Soichiro Ebisawa
Ayako Okada
Hirohiko Motoki
Uichi Ikeda
Koichiro Kuwahara
The REASON Investigators
Publication date
09-04-2022
Publisher
Springer Japan
Published in
Heart and Vessels / Issue 9/2022
Print ISSN: 0910-8327
Electronic ISSN: 1615-2573
DOI
https://doi.org/10.1007/s00380-022-02060-9

Other articles of this Issue 9/2022

Heart and Vessels 9/2022 Go to the issue